Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28586012 | 1.00 | MAPK1 (0.53) | MAPK1EPHX2TDP1LMNAALDH1A1 | |
| SCHEMBL4270527 | 1.00 | MAPK1 (0.53) | MAPK1EPHX2TDP1LMNAALDH1A1 | |
| SCHEMBL2146121 | 0.93 | EPHX2 (0.58) | MAPK1EPHX2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL4779124 | 0.89 | ALDH1A1 (0.54) | MAPK1EPHX2ALDH1A1L3MBTL1NPSR1 | |
| SCHEMBL16992397 | 0.89 | MAPK1 (0.55) | MAPK1EPHX2TDP1LMNAALDH1A1 | |
| SCHEMBL29117235 | 0.84 | ALDH1A1 (0.60) | MAPK1EPHX2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL29117233 | 0.84 | ALDH1A1 (0.60) | MAPK1EPHX2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL1624691 | 0.81 | KDM5A (0.52) | ALDH1A1 | |
| SCHEMBL1437945 | 0.81 | EPHX2 (0.61) | MAPK1EPHX2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL12713904 | 0.80 | MAPK1 (0.48) | MAPK1EPHX2TDP1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113149972-B | 2- (aryl (azacycloalkane-1-yl) methyl) phenol derivatives and use thereof | 四川大学 | 2022-09-13 | — | — | CN | disclosed |
| CN-113149972-A | 2- (aryl (azacycloalkane-1-yl) methyl) phenol derivatives and use thereof | 四川大学 | 2021-07-23 | — | — | CN | disclosed |
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | US | disclosed |
| EP-2035409-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANATGONIST FOR THE CB1-RECEPTOR | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008036021-A1 | TETRAHYDRO-LH-PYRIDO [3,4 -B] INDOLE DERIVATIVES AS CBL RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007145563-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | CNR1, CNR2, CCKAR | MAPK1 2437/4885EPHX2 2170/4885TDP1 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.